Hybridan Small Cap Feast: 28/11/2023

*A corporate client of Hybridan LLP
** Arranged by most recent first
*** Alphabetically arranged

Dish of the day
Joiners:  
No joiners today. 

Leavers:  
No leavers today.

What’s cooking in the IPO kitchen?** 

23 November — Substrate Artificial Intelligence ITF: An artificial intelligence Company based in Spain that creates, buys and scales companies around AI in diverse sectors such as fintech, agritech, energy, human resources, and health announces its Admission to the Aquis Growth Market. Expected AQSE Admission date is on or around the 7 December 2023.

15 November —Afentra Plc ITF: Formerly Sterling Energy plc, and launched in 2021 to support the African energy transition as a independent oil and gas company announces its Admission to AIM pursuant to the Sonangol Acquisition which constitutes a reverse takeover and therefore admission is being sought as a result of such reverse take-over. The Company will not be raising new capital as part of its Admission. Anticipated market capitalisation on Admission will be c.£65m. Expected AIM Admission date is expected mid-December.

9 November: Chapel Down Group ITF:  England's leading and largest wine producer with an award-winning range of sparkling and still wines, under the Chapel Down brand. The Company owns, leases and sources from 1,023 acres of vineyards in South East England announces its Admission to AIM after its transfer from the Aquis Apex market. The Company will not be raising new capital or providing a secondary offering as part of its Admission. Anticipated market capitalisation on Admission will be c.£75m. Expected AIM Admission date is 7 December 2023.

2 October: Tekcapital announced intention to spin off and IPO: MicroSalt, the developer of salt-producing technology designed to deliver full flavor with less sodium, announces the launch of an exempt public offer of shares to retail investors for up to £2.5m via PrimaryBid as part of its spin out from AIM listed Tekcapital plc (TEK.L). Microsalt announced revenues of US$0.638m in 2022, its first year of retail sales of SaltMe Crisp brand and Microsalt salt shakers in US based supermarkets and through Amazon US. AIM Admission delayed, expected mid-December.

Banquet Buffet*** 

Alien Metals 0.3p  £19.1m (UFO.L)

A minerals exploration and development Company announces it has entered into a conditional, non-binding Memorandum of Understanding (MoU) with Pilbara Ports to access its Utah Bulk Handling Facility (Utah Point). The MoU aids the Iron Ore Company of Australia Pty Ltd (IOCA) to access the common-use stockpiles at Utah Point and export up to 1.25m tonnes per annum of Iron Ore from Q4 2024. IOCA also announces that the next step in this process has progressed to a point whereby Pilbara Ports and IOCA have agreed the terms of the binding agreement for iron ore export through Utah Point, subject to regulatory approvals.

Ariana Resources 2.15p £24.6m (AAU.L)

The mineral exploration and development Company with gold mining interests in Europe announces results from a recent drilling programme at the Kizilcukur Project. Process metallurgical testwork of the Kizilcukur mineralisation yields an average gold recovery of 97%, significantly higher than Kiziltepe and a rock-chip sampling programme designed to test the extensions to outcropping zones returned grades up to 15.47g/t Au.

Crimson Tide 160p £10.5m (TIDE.L)

The provider of the mpro5 solution provides a trading update. The Company expects to deliver EBITDA performance in FY23 of no less than £0.4m (FY22: LBITDA -£0.4m), ahead of the Board's prior expectation and a reduced loss before tax of  c.£-0.7m (FY22: -£1.7m). Loss after tax is expected to be reduced to £-0.3m (FY22 -£-1.2m) and FY23 turnover is expected to be in line with the Board's current expectations. The Group's current cash position stands at £2.8m, with an R&D tax refund of an anticipated minimum of £0.3m due imminently.  The Group is continuing to deliver its objective to build a high growth long-term SaaS business with strong recurring revenues.

Crossword Cybersecurity* 8.5p £8.0m (CCS.L)

The cybersecurity solutions Company focused on cyber strategy and risk announces a trading update for the year ending 31 December 2023. In the first half of 2023 Crossword shifted its focus to establishing a clear path to profitability with its current suite of products and dedicated staff, which continues to be their strategy. In the second half of 2023, revenue growth has not been as strong as expected and conversion from pipeline to contracts has slowed. Crossword expects FY23 revenue to be in the range of £4.1m to £4.3m, as opposed to the previously guided £6m of revenue. Net losses before taxation expected to be broadly in line with current market expectations. The Company has previously guided to 2024 revenue of c£8m, but now believes that revenue is more likely to be c.£7m for 2024.

Fusion Antibodies 3.95p £2.3m (FAB.L)

A Company focusing on pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications announces that it has signed a collaboration agreement with the National Cancer Institute (NCI) for the use of OptiMAL in the discovery of novel antibodies against targets selected by NCI. Under the terms, Fusion will provide access to the OptiMAL technology to NCI for deployment against an agreed number of targets, being primarily cancer targets, over a period of up to two years following which, OptiMAL technology and jointly publish any results from the collaboration.

Good Energy Group 362p £61.2m (GOOD.L)

The 100% renewable electricity supplier and energy services provider issues a trading update for the 10 months to 31 October 2023. Good Energy expects to deliver earnings ahead of the Board's expectations for the full year seeing a profit before tax of at least £4m. The forecast loss in H2 2023 is now expected to be reduced, as weather conditions through the early winter have been generally mild and renewable generation has been stable. The Company's trading to the end of October has been ahead of expectations.

Journeo 230p £37.9m (JNEO.L)

A provider of information systems and technical services to transport operators and local authorities reports an update on trading for the year ending 31 December 2023 (FY 2023). The Group expects to deliver revenue for FY 2023 of approximately £46m, ahead of market expectations. Strong sales order intake in Journeo's core Fleet Operator Systems and Passenger Information Systems businesses continues past £27m achieved for FY 2022 giving good forward earnings visibility into FY 2024. The Company expects adjusted profit before tax of c.£3.9m ahead of market expectations.

Kinovo 49.5p  £31.1m (KINO.L)

The property services group that delivers compliance and sustainability solutions announces its unaudited interim results for the six months ended 30 September 2023 (Period). Revenue increased by 2% to £30.3m (H1 2023: £29.8m), as a result, gross profit is up 9% from £7.71m to £8.40m, adjusted EBITDA is up 21% to £2.9m (H1 2023: £2.4m) and the Company holds net cash of £1.0m (H1 2023, net debt: £56k). The Company announce that their three-year visible revenues increased to £157.0m (FY 2023: £146.4m) with 95% of revenues recurring and their satellite office is established in Dereham, Norfolk following strong interest in the Company’s services in the East of England. The Group is trading in line with the Board's expectations for the full year.

Molecular Energies 89p £9.2m (MEN.L)

The international energy Company provides an update relating to G-Mobility and CPH2. G-Mobility, a subsidiary of Green House Capital, the green division of Molecular which is progressing a spin out and IPO notes the RNS announcement of Clean Power Hydrogen PLC (CPH2) made today in relation to a non-binding framework agreement having been signed between G-Mobility and CPH2.Under the non-binding framework agreement the parties will explore a licensing arrangement for the manufacture and sale of CPH2's electrolysers in the Mercosur trading bloc of countries in South America.

Totally 6.6p £13.0m (TLY.L)

A provider of frontline healthcare services, corporate fitness and wellbeing services across the UK and Ireland announces the appointment of Simon Stilwell to the Board of Directors with immediate effect. Simon Stilwell will initially join the Board as a Non-Executive Director and as Chairman designate and will become the Company's Non-Executive Chairman with effect from 1 January 2024. Simon is currently a Non-Executive Director of Gresham House plc and has over 26 years' experience in the City.

Status of this Note and Disclaimer
This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of the UK retained version of section B of annex I to Directive 2014/65/EU ("MIFID II Directive"); or (ii) investment research as defined in the UK retained version of article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II       Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority's Conduct of Business Sourcebook).
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii)  persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.